Trial Profile
The effects of AD047 and AD282 on obstructive sleep apnoea (OSA)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 16 May 2019
Price :
$35
*
At a glance
- Drugs Sleep apnoea therapeutic-Apnimed (Primary)
- Indications Sleep apnoea syndrome
- Focus Therapeutic Use
- Sponsors Apnimed
- 15 May 2019 Status changed from recruiting to completed.
- 14 Dec 2018 Status changed from not yet recruiting to recruiting.
- 23 Jul 2018 New trial record